

ΚΥΠΡΙΑΚΟ ΓΡΑΦΕΙΟ ΔΙΠΛΩΜΑΤΩΝ ΕΥΡΕΣΙΤΕΧΝΙΑΣ

THE PATENT OFFICE OF CYPRUS

ΑΡΙΘΜΟΣ ΔΗΜΟΣΙΕΥΣΗΣ **CY1254**
PUBLICATION NUMBER

ΑΡΙΘΜΟΣ ΔΗΜΟΣΙΕΥΣΗΣ
ΓΡΑΦΕΙΟΥ ΔΙΠΛΩΜΑΤΩΝ ΕΥΡΕΣΙΤΕΧΝΙΑΣ
ΗΝΩΜΕΝΟΥ ΒΑΣΙΛΕΙΟΥ
UK PATENT OFFICE
PUBLICATION NUMBER GB2029700

Το έγγραφο που παρουσιάζεται πιο κάτω καταχωρήθηκε στο «Γραφείο Διπλωμάτων Ευρεσιτεχνίας» στην Αγγλία σύμφωνα με το Νόμο Κεφ. 266 πριν την 1η Απριλίου 1998. Δημοσίευση έγινε μετέπειτα από το Γραφείο Διπλωμάτων Ευρεσιτεχνίας του Ηνωμένου Βασιλείου μόνο στην Αγγλική γλώσσα.

The document provided hereafter was filed at "The Patent Office" in England under the law CAP.266 before the 1st of April 1998. It was published afterwards by the UK patent office only in English.

(12) UK Patent Application (19) GB (11) 2 029 700 A

(21) Application No **7926364**
(22) Date of filing **27 Jul 1979**
(23) Claims filed **27 Jul 1979**
(30) Priority data
(31) **942236**
(32) **14 Sep 1978**
(33) **United States of America (US)**
(43) Application published **26 Mar 1980**
(51) **INT CL³**
A61K 31/415 9/08
(52) Domestic classification
A5B 180 38Y 392 402 40Y 443 44Y 501 50Y 542 54Y 565 56Y 586 58Y 661 66Y 823 833 J L N
(56) Documents cited
GB 1064631
The Extra Pharmacopoeia (Martindale) 27th Edition. (N) Pp 1756—1757 under the monograph entitled "Etomidate Sulphate".
(58) Field of search
A5B
C2C
(71) Applicants
Janssen Pharmaceutica N.V., Turnhoutsebaan, 30, B-2340 Beerse, Belgium
(72) Inventor
Jean Mesens
(74) Agents
Boult, Wade & Tennant

(54) Etomidate-containing compositions

(57) Etomidate-containing compositions for intravenous administration comprise a physiologically acceptable infusion liquid to which has been added a solution of etomidate hydrochloride or hydrobromide in a solvent containing at least 80% by weight of ethanol. The infusion solutions are used for maintenance anaesthetics. Etomidate is R-(+)ethyl 1-(1-phenylethyl 1-H-imidazole-5-carboxylate.

GB 2 029 700 A

SPECIFICATION

Etomidate-containing compositions

This invention relates to etomidate-containing compositions, suitable for intravenous administration and a method of preparing the same. The compositions may be intravenously administered to a patient in need of them.

Etomidate, being chemically designated as R-(+) ethyl 1-(1-phenylethyl)1H-imidazole-5-carboxylate is a short-acting hypnotic agent, belonging to the class of alkyl 1-(1-phenylalkyl)-1H-imidazole-5-carboxylates which are described in U.S. Pat. No. 3,354,173. More detailed data concerning the hypnotic properties of etomidate presented in Arzneimittel-Forschung (Drug Research), *21*, 1234 (1971).

More recently, etomidate has been demonstrated to be useful as a maintenance anaesthetic which can be used as a substitute for the classical inhalation anaesthetics such as nitrous oxide, halothane and the like. Reports on such utility can be found in Acta anaesth. belg., *28*, 107 (1977) and ibid., *28*, 115 (1977). It is evident that, in view of its short duration of action, etomidate, when used as a maintenance anaesthetic, has to be administered repeatedly or continuously during a certain time interval in order to maintain an effective level of the drug in the patient's blood. This goal can be achieved by administering etomidate in the form of an intravenous infusion at a predetermined rate.

One of the major problems which have been encountered in the course of this development was to find a suitable pharmaceutical composition to be used for the above purpose. It is obvious that such composition must be fully acceptable for the particular, i.e. intravenous way of administration. Moreover the composition should be stable, or, it should be possible to prepare the composition in a convenient and quick manner starting from stable components. Preferably such composition should essentially consist of a solution of the drug in a normal aqueous infusion liquid such as saline, glucose solution or a mixture of saline and glucose solution.

None of the previously known compositions completely fulfils the above criteria.

Etomidate is known to be only slightly soluble in neutral aqueous medium. Its solubility is much better in acid medium or in organic solvents such as alcohol and chloroform (see Arzneimittel-Forschung (Drug Research), *21*, 1234 (1971). Two types of etomidate-containing compositions which take advantage of the latter properties have been described in the literature.

A first composition, which has been described in Arzneimittel-Forschung (Drug Research) *21*, 1234 (1971) comprises a solution of etomidate-base in 60% aqueous propylene glycol. The composition is obviously not acceptable as such for intravenous infusion in view of its very high content of propylene glycol. When diluting the solution with normal infusion liquid some precipitation may occur and this can only be eliminated by vigorous stirring during a rather long time and provided that the final concentration of etomidate in the solution is below about 0.5mg/ml. Moreover it has been found that etomidate when stored in propylene glycol undergoes to certain degree transesterification.

Another composition, which has been described in Anaesthesiology and Resuscitation, *106*, 1, Berlin-Heidelberg-New York (1977) comprises etomidate sulfate in phosphate buffer to which has been added 4.2% of glucose. The composition is physiologically acceptable but not very stable, etomidate being rapidly hydrolyzed in acidic aqueous medium. An extemporaneous preparation of this composition is not very easy since it requires dissolving a very small quantity of etomidate sulfate in a large volume of buffer. Under these conditions it is rather difficult to ascertain whether the solid has already completely dissolved in the medium. Moreover it has proven difficult to obtain completely dust-free etomidate sulfate which is obviously required for this type of formulation. Concentrated solutions of etomidate sulfate in aqueous medium, to be further diluted with buffer are not practical because they are not stable for the above-indicated reasons.

By the present invention there is provided an etomidate containing composition which is well-suited for intravenous administration, which need contain only a minimal amount of organic solvents and which can be prepared very easily and quickly by simply mixing two stable and uncomplicated solutions.

More particularly the present invention provides an etomidate-containing infusion liquid for intravenous administration which comprises a physiologically acceptable infusion liquid to which has been added a concentrated solution of etomidate hydrochloride or hydrobromide in a medium which contains at least 80% by weight of ethanol.

Physiologically acceptable infusion liquids which may advantageously be used for the present purpose are preferably isotonic with blood such as, for example, the standard physiologically acceptable saline and glucose solutions and mixtures of such saline and glucose solutions. Although the hydrobromide salt of etomidate is quite acceptable, the use of the hydrochloride salt is preferred. Besides etomidate hydrochloride or hydrobromide the medium may obviously contain other solvents and/or substances which do not adversely affect the stability and the efficacy of the composition nor its ability to be diluted with physiological liquid.

Although the presence of water enhances the rate of hydrolysis of etomidate in the solution and thus negatively influences the stability of the product it has been found that the medium may contain up to about 20% by weight of water. Lower concentrations of water in the medium, particularly below 5% by weight are however preferred and in an especially preferred embodiment the water-content of the medium is less than 0.5% by weight. In a most preferred

embodiment the medium consists of absolute ethanol.

The concentration of etomidate in the composition for intravenous (i.v.) administration may vary within rather wide limits depending on the rate of infusion and the dose required by the specific circumstances. Concentrations ranging from about 0.05 to about 5mg etomidate per ml, calculated on etomidate base content, have been found adequate. The concentration of the drug in the ethanolic solution is in general at least 10 times higher than that in the i.v. composition in order to keep the concentration of ethanol in the i.v. composition below physiologically acceptable limits.

The invention includes an etomidate-containing infusion liquid for intravenous administration which comprises a physiologically acceptable infusion liquid to which has been added a solution of etomidate hydrochloride or hydrobromide in a solvent which contains at least 80% by weight of ethanol.

The invention is further illustrated by the following example which by no way is limited the scope thereof.

EXAMPLE

A. Preparation of ampoules containing an ethanolic solution of etomidate-hydrochloride at a concentration 250mg etomidate base per 2ml. (Solution A)

143g of etomidate hydrochloride (corresponding to 125g base) are dissolved in absolute ethanol (99.8%) while stirring. The solution is filtered dust-free over a membrane filter of pore size 1,2μ. The solution is further sterilized by filtration over a membrane filter (pore size 0,2μ) and filled into 2ml ampoules. The latter are sealed and autoclaved at 120°C for 20 minutes.

B. Preparation of etomidate-containing infusion liquid

An etomidate-containing infusion liquid containing 1mg of etomidate base per ml is prepared by adding 2ml of solution A to 250ml of physiological saline or glucose solution. The composition is suitable for intravenous administration to a patient in need of same.

CLAIMS

1. An etomidate-containing infusion liquid for intravenous administration which comprises a physiologically acceptable infusion liquid to which has been added a solution of etomidate hydrochloride or hydrobromide in a solvent which contains at least 80% by weight of ethanol.

2. An infusion liquid as claimed in claim 1, prepared by adding to the physiologically acceptable infusion liquid a solution of etomidate hydrochloride or hydrobromide in absolute ethanol.

3. An infusion liquid as claimed in claim 1 or claim 2, containing from about 0.05 to about 5mg per ml of etomidate measured as base.

4. An infusion liquid containing etomidate substantially as hereinbefore described in the Example.

5. A method of preparing an etomidate-containing infusion liquid for intravenous administration which comprises adding to a physiologically acceptable infusion liquid a solution of etomidate hydrochloride in a medium which contains at least 80% by weight of ethanol.

6. A method as claimed in claim 5, wherein the solution of etomidate hydrochloride or hydrobromide is in absolute ethanol.

7. A solution in a solvent containing at least 80% by weight of ethanol of etomidate hydrochloride or hydrobromide, suitable for intravenous administration upon dilution with a physiologically acceptable liquid.

8. A solution as claimed in claim 7, being a dust-free solution of etomidate hydrobromide or hydrochloride in absolute ethanol sealed in an ampoule.

9. A solution as claimed in claim 7, substantially as hereinbefore described.

Printed for Her Majesty's Stationery Office by the Courier Press, Leamington Spa, 1980. Published by the Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.